These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31931515)

  • 1. A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.
    Pardo JV; Sheikh SA; Schwindt G; Lee JT; Adson DE; Rittberg B; Abuzzahab FS
    PLoS One; 2020; 15(1):e0226486. PubMed ID: 31931515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
    Brunner E; Tohen M; Osuntokun O; Landry J; Thase ME
    Neuropsychopharmacology; 2014 Oct; 39(11):2549-59. PubMed ID: 24801768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.
    Li CT; Chen MH; Lin WC; Hong CJ; Yang BH; Liu RS; Tu PC; Su TP
    Hum Brain Mapp; 2016 Mar; 37(3):1080-90. PubMed ID: 26821769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Accelerated HF-rTMS on the Subgenual Anterior Cingulate Cortex in Refractory Unipolar Major Depression: Insights From 18FDG PET Brain Imaging.
    Baeken C; Marinazzo D; Everaert H; Wu GR; Van Hove C; Audenaert K; Goethals I; De Vos F; Peremans K; De Raedt R
    Brain Stimul; 2015; 8(4):808-15. PubMed ID: 25744500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.
    Houston JP; Lau K; Aris V; Liu W; Fijal BA; Heinloth AN; Perlis RH
    J Clin Psychiatry; 2012 Jun; 73(6):878-85. PubMed ID: 22480387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation.
    Paillère Martinot ML; Martinot JL; Ringuenet D; Galinowski A; Gallarda T; Bellivier F; Lefaucheur JP; Lemaitre H; Artiges E
    Neuropsychopharmacology; 2011 Dec; 36(13):2710-9. PubMed ID: 21849980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opposite subgenual cingulate cortical functional connectivity and metabolic activity patterns in refractory melancholic major depression.
    Wu GR; De Raedt R; Van Schuerbeek P; Baeken C
    Brain Imaging Behav; 2020 Apr; 14(2):426-435. PubMed ID: 30519995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
    Tohen M; Case M; Trivedi MH; Thase ME; Burke SJ; Durell TM
    J Clin Psychiatry; 2010 Apr; 71(4):451-62. PubMed ID: 20361905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Corya SA; Williamson D; Sanger TM; Briggs SD; Case M; Tollefson G
    Depress Anxiety; 2006; 23(6):364-72. PubMed ID: 16710853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amygdala and regional volumes in treatment-resistant versus nontreatment-resistant depression patients.
    Sandu AL; Artiges E; Galinowski A; Gallarda T; Bellivier F; Lemaitre H; Granger B; Ringuenet D; Tzavara ET; Martinot JL; Paillère Martinot ML
    Depress Anxiety; 2017 Nov; 34(11):1065-1071. PubMed ID: 28792656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
    J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
    Thase ME; Corya SA; Osuntokun O; Case M; Henley DB; Sanger TM; Watson SB; Dubé S
    J Clin Psychiatry; 2007 Feb; 68(2):224-36. PubMed ID: 17335320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation.
    Lee CW; Chen YJ; Wu HF; Chung YJ; Lee YC; Li CT; Lin HC
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jul; 93():102-113. PubMed ID: 30940482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression.
    Bewernick BH; Hurlemann R; Matusch A; Kayser S; Grubert C; Hadrysiewicz B; Axmacher N; Lemke M; Cooper-Mahkorn D; Cohen MX; Brockmann H; Lenartz D; Sturm V; Schlaepfer TE
    Biol Psychiatry; 2010 Jan; 67(2):110-6. PubMed ID: 19914605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study.
    Bauer M; Berman S; Stamm T; Plotkin M; Adli M; Pilhatsch M; London ED; Hellemann GS; Whybrow PC; Schlagenhauf F
    Mol Psychiatry; 2016 Feb; 21(2):229-36. PubMed ID: 25600111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression: a resting-state fMRI study using fractional amplitude of low-frequency fluctuations.
    Yamamura T; Okamoto Y; Okada G; Takaishi Y; Takamura M; Mantani A; Kurata A; Otagaki Y; Yamashita H; Yamawaki S
    Transl Psychiatry; 2016 Mar; 6(3):e754. PubMed ID: 26954981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional connectivity of the anterior cingulate cortex predicts treatment outcome for rTMS in treatment-resistant depression at 3-month follow-up.
    Ge R; Downar J; Blumberger DM; Daskalakis ZJ; Vila-Rodriguez F
    Brain Stimul; 2020; 13(1):206-214. PubMed ID: 31668646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.
    Carlson PJ; Diazgranados N; Nugent AC; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Manji HK; Zarate CA; Drevets WC
    Biol Psychiatry; 2013 Jun; 73(12):1213-21. PubMed ID: 23540908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
    J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blunted amygdala activity is associated with depression severity in treatment-resistant depression.
    Ferri J; Eisendrath SJ; Fryer SL; Gillung E; Roach BJ; Mathalon DH
    Cogn Affect Behav Neurosci; 2017 Dec; 17(6):1221-1231. PubMed ID: 29063521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.